Deficiency of serum concentration of 25-Hydroxyvitamin D in psoriatic patients: A case-Control study

Journal of the American Academy of Dermatology

Volumn 67, Issue 5, 2012, Pages 931-938

  Orgaz Molina, Jacinto ^a   Buendía Eisman, Agustín ^b   Arrabal Polo, Miguel A ^b   Ruiz, José Carlos ^a   Arias Santiago, Salvador ^a,b,c  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c Baza Hospital   (Spain)

Author keywords

25 hydroxyvitamin D; Autoimmunity; Body mass index; C reactive protein; Psoriasis; Psoriasis Area and Severity Index

Indexed keywords

C REACTIVE PROTEIN; HYDROXYCOLECALCIFEROL;

ADULT; ARTICLE; AUTOIMMUNITY; BLOOD; BODY MASS; CASE CONTROL STUDY; FEMALE; HUMAN; MALE; MULTIVARIATE ANALYSIS; OBESITY; PSORIASIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; VITAMIN D DEFICIENCY;

ADULT; AUTOIMMUNITY; BODY MASS INDEX; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; OBESITY; PSORIASIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; VITAMIN D DEFICIENCY;

EID: 84871669833     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2012.01.040     Document Type: Article

References (56)

1. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866-73
2. Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994;102:145-9
3. Clemens TL, Garrett KP, Zhou XY, Pike JW, Haussler MR, Dempster DW. Immunocytochemical localization of the 1,25-dihydroxyvitamin-D3 receptor in target cells. Endocrinology 1988;122:1224-30
4. Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998;13:325-49
5. Stumpf WE, Sar M, Clark SA, DeLuca HF. Brain target sites for 1,25-dihydroxyvitamin D3. Science 1982;215:1403-5
6. Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM, et al. Extrarenal expression of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 2001;86: 888-94
7. Bhalla AK, Amento EP, Clemens TL, Holick MF, Krane SM. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: Presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab 1983;57:1308-10
8. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1,25-Dihydroxyvitamin D3 receptors in human leukocytes. Science 1983;221:1181-3
9. Zold E, Barta Z, Bodolay E. Vitamin D deficiency and connective tissue disease. Vitam Horm 2011;86:261-86
10. Dubertret L, Wallach D, Souteyrand P, Perussel M, Kalis B, Meynadier J, et al. Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris: A randomized, double-blind, right/left comparative, vehicle-controlled study. J Am Acad Dermatol 1992;27:983-8
11. Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG. Vitamin D intake is inversely associated with rheumatoid arthritis: Results from the Iowa Women's Health Study. Arthritis Rheum 2004;50:72-7
12. Devaraj S, Yun JM, Duncan-Staley CR, Jialal I. Low vitamin D levels correlate with the proinflammatory state in type 1 diabetic subjects with and without microvascular complications. Am J Clin Pathol 2011;135:429-33
13. Nieves J, Cosman F, Herbert J, Shen V, Lindsay R. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 1994;44:1687-92
14. Ono Y, Suzuki A, Kotake M, Zhang X, Nishiwaki-Yasuda K, Ihiwata Y, et al. Seasonal changes of serum 25-hydroyvitamin D and intact parathyroid hormone levels in a normal Japanese population. J Bone Metab 2005;23:147-51
15. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitaminD3: Exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 1988;67:373-8
16. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357: 266-81
17. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006;81:353-73
18. Holick MF. Vitamin D requirements for humans of all ages: new increased requirements for women and men 50 years and older. Osteoporosis Int 1998;8:24-9
19. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004;80:1678-88
20. Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, Gilkeson GS. Vitamin D deficiency in systemic lupus erythematosus. Autoimmune Rev 2006;5:114-7
21. Arunabh S, Pollack S, Yeh J, Aloia JF. Body fat content and 25-hydroxyvitamin D levels in healthy women. J Clin Endocrinol Metab 2003;88:157-61
22. Frost M, Abrahamsen B, Nielsen TL, Hagen C, Andersen M, Brixen K. Vitamin D status and PTH in young men: A cross-sectional study on associations with bone mineral density body composition and glucose metabolism. Clin Endocrinol 2010;73:573-80
23. Vilarrasa N, Maravall J, Estepa A, Sanchez R, Masdevall C, Navarro MA, et al. Low 25-hydroxyvitamin D concentrations in obese women: Their clinical significance and relationship with anthropometric and body composition variables. J Endocrinol Invest 2007;30:653-8
24. Ybarra J, Sanchez-Hernandez J, Perez A. Hypovitaminosis D and morbid obesity. Nurs Clin North Am 2007;42:19-27
25. Worstman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000;72:690-3
26. Florez H, Martinez R, Chacra W, Strickman-Stein N, Levis S. Outdoor exercise reduces the risk of hypovitaminosis D in the obese. J Steroid Biochem Mol Biol 2007;103:679-81
27. Moan J, Lagunova Z, Lindberg FA, Porojnicu AC. Seasonal variation of 1,25 dihydroxyvitamin D and its association with body mass index and age. J Steroid Biochem Mol Biol 2009; 113:217-21
28. Bischof MG, Heinze G, Vierhapper H. Vitamin D status and its relation to age and body mass index. Horm Res 2006;66: 211-5
29. Ockene IS, Chiriboga DE, Stanek EJ, Harmatz MG, Nicolosi R, Saperia G, et al. Seasonal variation in serum cholesterol levels: Treatment implications and possible mechanisms. Arch Intern Med 2004;164:863-70
30. Rucker D, Allan JA, Fick GH, Hanley DA. Vitamin D insufficiency in a population of healthy western Canadians. CMAJ 2002;166: 1517-24
31. Kudlacek S, Schneider B, Peterlik M, Leb G, Klaushofer K, Weber K, et al. Assessment of vitamin D and calcium status in healthy adult Austrians. Eur J Clin Invest 2003;33:323-31
32. Visscher BR, Detels R, Coulson AH, Malmgren RM, Dudley JP. Latitude, migration, and the prevalence of multiple sclerosis. Am J Epidemiol 1977;106:470-5
33. Goodkin DE, Hertsgaard D. Seasonal variation of multiple sclerosis exacerbations inNorthDakota. ArchNeurol 1989;46:1015-8
34. Wuthrich R, Rieder HP. The seasonal incidence of multiple sclerosis in Switzerland. Eur Neurol 1970;3:257-64
35. Auer DP, Schumann EM, Kumpfel T, Gossl C, Trenkwalder C. Seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2000; 47:276-7
36. Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001;15:16-7
37. Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys 2000;374:334-8
38. Overbergh L, Stoffels K, Waer M, Verstuyf A, Bouillon R, Mathieu C. Immune regulation of 25-hydroxyvitamin D-1-alpha- hydroxylase in human monocytic THP1 cells: mechanisms of interferon-mediated induction. J Clin Endocrinol Metab 2006;91:3566-74
39. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: A birth cohort study. Lancet 2001;358:1500-3
40. Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D (3) analogs as immunomodulatory agents. Trends Mol Med 2002;8:174-9
41. Lemire JM, Archer DC, Beck L, Spiegelberg HL. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: Preferential inhibition of Th1 functions. J Nutr 1995;125(Suppl):1704-8
42. Muller K, Bendtzen K. 1,25-Dihydroxyvitamin D3 as a natural regulator of human immune functions. J Invest Dermatol Symp Proc 1996;1:68-71
43. Manolagas SC, Hustmyer FG, Yu XP. Immunomodulating properties of 1,25-dihydroxyvitamin D3. Kidney Int Suppl 1990;29:S9-16
44. Rausch-Fan X, Leutmezer F, Willheim M, Spittler A, Bohle B, Ebner C, et al. Regulation of cytokine production in human peripheral blood mononuclear cells and allergen-specific th cell clones by 1alpha,25-dihydroxyvitamin D3. Int Arch Allergy Immunol 2002;128:33-41
45. Cantorna MT. Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? Proc Soc Exp Biol Med 2000;223:230-3
46. Zella JB, DeLuca HF. Vitamin D and autoimmune diabetes. J Cell Biochem 2003;88:216-22
47. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 1996;93:7861-4
48. Silverberg JI, Silverberg AI, Malka E, Silverberg NB. A pilot study assessing the role of 25 hydroxy vitamin D levels in patients with vitiligo vulgaris. J Am Acad Dermatol 2010;62: 937-41
49. Werner de Castro GR, Neves FS, Pereira IA, Fialho SC, Ribeiro G, Zimmermann AF. Resolution of adalimumab-induced psoriasis after vitamin D deficiency treatment. Rheumatol Int doi: 10.1007/s00296-011-1799-9. Published online February 3, 2011
50. Perez A, Raab R, Chen TC, Turner A, Holick MF. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 1996;134:1070-8
51. Gaál J, Lakos G, Szodoray P, Kiss J, Horváth I, Horkay E, et al. Immunological and clinical effects of alphacalcidol in patients with psoriatic arthropathy: Results of an open, follow-up pilot study. Acta Derm Venereol 2009;89:140-4
52. Huckins D, Felson DT, Holick M. Treatment of psoriatic arthritis with oral 1,25-dihydroxyvitamin D3: A pilot study. Arthritis Rheum 1990;33:1723-7
53. Park BS, Park JS, Lee DY, Youn JI, Kim IG. Vitamin D receptor polymorphism is associated with psoriasis. J Invest Dermatol 1999;112:113-6
54. Bouillon R. Genetic and environmental determinants of vitamin D status. Lancet 2010;376:148-9
55. Chodorowska G, Wojnowska D, Juszkiewicz-Borowiec M. C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis. J Eur Acad Dermatol Venereol 2004;18:180-3
56. Ngo DT, Sverdlov AL, McNeil JJ, Horowitz JD. Does vitamin D modulate asymmetric dimethylarginine and C-reactive protein concentrations? Am J Med 2010;123:335-41.